Literature DB >> 1519534

Reversal of human platelet aggregation by low concentrations of nitroglycerin in vitro in normal subjects.

Y Y Chirkov1, J I Naujalis, S Barber, R E Sage, D W Gove, J K Brealey, J D Horowitz.   

Abstract

The potential reversal of platelet aggregation in vitro by nitroglycerin in low concentrations was explored using both optical aggregometry and electron microscopy. Venous blood was collected from a cohort of normal volunteers (20 men and 10 women) aged 21 to 65 years. Aggregation in platelet-rich plasma was induced by adenosine diphosphate in concentrations just sufficient to maintain a steady state of aggregation, without a spontaneous disaggregation phase (3.5 to 5 microM). Administration of nitroglycerin after the induction of aggregation caused both inhibition of the primary wave of developing aggregation and marked disaggregation. This combined effect was maximal when nitroglycerin was added at 0.5 minute after the beginning of aggregation. The observed reversal of platelet aggregation by nitroglycerin was concentration-dependent. Significant effects occurred with nitroglycerin concentrations greater than or equal to 10(-8) M. Concentration associated with 50% reversal of aggregation was 1.52 +/- 0.24 (SEM) x 10(-6) M. Electron microscopy revealed that 10(-6) M nitroglycerin induced a significant reduction in both platelet clumping and morphologic changes associated with aggregation. The results of the current study suggest a beneficial antiplatelet effect of nitroglycerin in restoring homeostasis in the face of incipient platelet aggregation. The clinical use of nitroglycerin in patients with acute ischemic syndromes may rest on this action.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1519534     DOI: 10.1016/0002-9149(92)90563-e

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance.

Authors:  Andrew S Holmes; Yuliy Y Chirkov; Scott R Willoughby; Susan Poropat; Jeremy Pereira; John D Horowitz
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

2.  Suppressed anti-aggregating and cGMP-elevating effects of sodium nitroprusside in platelets from patients with stable angina pectoris.

Authors:  Y Y Chirkov; L P Chirkova; J D Horowitz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

Review 3.  Daily life cardiac ischaemia. Should it be treated?

Authors:  B D Bertolet; C J Pepine
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

Review 4.  Mechanisms of action of nitrates.

Authors:  K E Torfgård; J Ahlner
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

5.  Discovery and Clinical Evaluation of MK-8150, A Novel Nitric Oxide Donor With a Unique Mechanism of Nitric Oxide Release.

Authors:  Clayton D Knox; Pieter-Jan de Kam; Karim Azer; Peggy Wong; Antwan G Ederveen; Diane Shevell; Christopher Morabito; Alan G Meehan; Wen Liu; Tom Reynders; Jean Francois Denef; Anna Mitselos; Daniel Jonathan; David E Gutstein; Kaushik Mitra; Shu Yu Sun; Michael Man-Chu Lo; Doris Cully; Amjad Ali
Journal:  J Am Heart Assoc       Date:  2016-08-25       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.